Development and in Vitro Evaluation of Multi/bi-bilayer Tablet Dual-release Formulations of Vildagliptin and Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus
Main Article Content
Abstract
Introduction: This study aimed to develop an innovative bilayer tablet formulation of dapagliflozin and vildagliptin to increase therapeutic outcomes and patient compliance in diabetes management. Methods: By employing wet granulation, immediate-release, and sustained-release layers were formulated using various super-disintegrating and release-retarding agents, respectively. Several pre-compression parameters were utilized, such as Carr’s index, Hausner ratio, physical attributes (weight variations, friability, hardness), and disintegration time. Drug-excipient interactions were determined through employing FTIR, SEM, DSC, and TGA. In-vitro dissolution studies were performed to assess the release kinetics of these formulations. Results: For immediate-release dapagliflozin, our earlier study demonstrated that the formulations showed Carr’s index (23.5-33.3), physical attributes (weight (145–155 mg), thickness (4.42 ± 0.04 -4.46 ± 0.05 mm), hardness (3.7-5.6 kg/cm2), friability (<1%), and optimized rapid dissolution (F1: 80.50% ± 5.2 in 30 minutes). For sustained-release vildagliptin, the formulations showed Carr’s index (10.48-20), physical attributes (weight (194-203 mg), thickness (3.32 ± 0.06-3.33±0.04 mm), hardness (4.8 ± 0.1-7.6 ± 0.2 kg/cm2), friability (<1%)), and optimized controlled release (A5: 81.76% ± 2.4 in 360 minutes). The results found that F1 and A5 were the optimum formulation for the immediate release of dapagliflozin, and the sustained release of vildagliptin, respectively, and BT-1 was the optimum bilayer tablet because of its rapid onset of action for dapagliflozin (84.23% within 60 minutes) and sustained release for vildagliptin (80.026% within 360 minutes). Conclusion: Based on these data, the optimized bilayer tablet holds the potential to be a convenient and effective treatment option. Further, in-vivo assays are necessary to confirm its efficacy and safety.
Downloads
Article Details
References
Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: An overview. Avicenna J Med. 2020 Oct 4;10(04):174–88. doi: 10.4103/ajm.ajm_53_20.
Sapra A, Bhandari P. Diabetes. [Updated 2023 Jun 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551501/.
Al-Badriyeh AD. Correction to ‘Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10-year forecasting model’. Diabetes Obes Metab. 2024 Apr 1;26(4):1552–1552. doi: 10.1111/dom.15452
Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TTKS, et al. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications—risks and mitigation. EPMA Journal. 2023 Feb 13;14(1):21–42. 1. doi: 10.1007/s13167-023-00314-8.
Solis-Herrera C, Triplitt C, Reasner C, et al. Classification of Diabetes Mellitus. [Updated 2018 Feb 24]. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. South Dartmouth (MA): 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279119/
Elhefnawy ME, Ghadzi SMS, Noor Harun S. Predictors Associated with Type 2 Diabetes Mellitus Complications over Time: A Literature Review. Journal of Vascular Diseases. 2022 Aug 4;1(1):13–23. doi: 10.3390/jvd1010003
Arroyave F, Montaño D, Lizcano F. Diabetes Mellitus Is a Chronic Disease that Can Benefit from Therapy with Induced Pluripotent Stem Cells. Int J Mol Sci. 2020 Nov 18;21(22):8685. doi: 10.3390/ijms21228685. PMID: 33217903; PMCID: PMC7698772.
Rodríguez-Gutiérrez R, Millan-Alanis JM, Barrera FJ, McCoy RG. Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes. Curr Diab Rep. 2021 Dec 13;21(12):63. doi: 10.1007/s11892-021-01433-0.
Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front Endocrinol (Lausanne). 2017 Jan 24;8. Doi: https://doi.org/10.3389/fendo.2017.00006.
Dawed AY, Yee SW, Zhou K, van Leeuwen N, Zhang Y, Siddiqui MK, et al. Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673–2682. Diabetes Care. 2022 Apr 1;45(4):e82–3. doi: https://doi.org/10.2337/dc21-1152
Buzzetti R, Zampetti S, Pozzilli P. Impact of obesity on the increasing incidence of type 1 diabetes. Diabetes Obes Metab. 2020 Jul 24;22(7):1009–13. doi: https://doi.org/10.1111/dom.14022
Wyne K, Bakris GL. Control of Blood Glucose and Insulin Resistance. In: Comprehensive Hypertension. Elsevier; 2007. p. 1105–12.
Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, et al. The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose. Diabetes Care. 2008 Jan 1;31(1):108–13. doi: https://doi.org/10.2337/dc07-1441
Beitelshees AL, Leslie BR, Taylor SI. Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research. Diabetes. 2019 Jun 1;68(6):1109–20. doi: https://doi.org/10.2337/dbi18-0006
Tong L, Adler S. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgrad Med. 2018 May 19;130(4):381–93. doi: 10.1080/00325481.2018.1457397.
Maladkar M, Yadav A, Anchan N. Patient-Driven Solutions: Integrating Vildagliptin and Dapagliflozin in Diabetes Management. International Journal of Diabetes and Endocrinology. 2024 May 10;9(2):39–45. doi: 10.11648/j.ijde.20240902.12.
Kaur G, Grewal J, Jyoti K, Jain UK, Chandra R, Madan J. Oral controlled and sustained drug delivery systems. In: Drug Targeting and Stimuli Sensitive Drug Delivery Systems. Elsevier; 2018. p. 567–626. doi: https://doi.org/10.1016/b978-0-12-813689-8.00015-x.
Akhtar M, Jamshaid M, Zaman M, Mirza AZ. Bilayer tablets: A developing novel drug delivery system. J Drug Deliv Sci Technol. 2020 Dec;60:102079. Doi: https://doi.org/10.1016/j.jddst.2020.102079
Patil SR, Atram SC, Sonar K V. Bilayer Tablet Technology: A Review. American Journal of PharmTech Research. 2019; doi:10.46624/ajptr.2019.v9.i6.018.
Bassetto R, Amadio E, Ciampanelli F, Perin S, Ilari P, Gaballo P, et al. Designing an effective dissolution test for bilayer tablets tailored for optimal melatonin release in sleep disorder management. Front Nutr. 2024 May 6;11. doi: 10.3389/fnut.2024.1394330.
Inoue H, Tamaki Y, Kashihara Y, Muraki S, Kakara M, Hirota T, et al. Efficacy of DPP‐4 inhibitors, GLP‐1 analogues, and SGLT2 inhibitors as add‐ons to metformin monotherapy in T2DM patients: a model‐based meta‐analysis. Br J Clin Pharmacol. 2019 Feb 6;85(2):393–402. doi: 10.1111/bcp.13807.
Fatima A, Rasool S, Devi S, Talha M, Waqar F, Nasir M, et al. Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management. Cureus. 2023 Sep 30; doi: 10.7759/cureus.46243.
Paul S, Uddin TM, Samadd MA, Rahim MA, Hossain MS, Sarkar MR, et al. In vitro assessment of immediate-release Dapagliflozin tablets for type 2 diabetes mellitus treatment. Bangladesh J Sci Ind Res. 2024;59(3):139–48. doi: 10.5564/bjsir.v59i3.73411
Mizumoto T, Masuda Y, Yamamoto T, Yonemochi E, Terada K. Formulation design of a novel fast-disintegrating tablet. Int J Pharm. 2005 Dec;306(1–2):83–90. doi: 10.1016/j.ijpharm.2005.09.009.
SUMA B V., R. D, SHENOY P. A NEW HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHIC METHOD DEVELOPMENT AND VALIDATION OF DAPAGLIFLOZIN IN BULK AND TABLET DOSAGE FORM. Int J Pharm Pharm Sci. 2019 Jul 15;58–63. doi:10.22159/ijpps.2019v11i8.34339
Wünsch I, Finke JH, John E, Juhnke M, Kwade A. The influence of particle size on the application of compression and compaction models for tableting. Int J Pharm. 2021 Apr;599:120424.
Kumar Jha S, Devanna C V, Parameshwar K, Radhika Reddy M. Formulation Development and Evaluation of Vildagliptin Sustained-release Tablet. International Journal of Drug Delivery Technology. 2018;8(4):180–6. doi: 10.25258/ijddt.v8i4.5
Shilpa V, Kiran K. Journal of Drug Development and Delivery Formulation Development and In-vitro Evaluation of Vildagliptin Controlled Release Tablets Article Information. 2019. Available from: www.innovationinfo.org
Unnisa A, Chettupalli AK, Al Hagbani T, Khalid M, Jandrajupalli SB, Chandolu S, et al. Development of Dapagliflozin Solid Lipid Nanoparticles as a Novel Carrier for Oral Delivery: Statistical Design, Optimization, In-Vitro and In-Vivo Characterization, and Evaluation. Pharmaceuticals. 2022 May 2;15(5):568. doi: 10.3390/ph15050568.
Berthomieu C, Hienerwadel R. Fourier transform infrared (FTIR) spectroscopy. Photosynth Res. 2009 Sep 10;101(2–3):157–70. doi: 10.1007/s11120-009-9439-x.
Sawant AR, Barhate SD, M.M.Bari, sonawne Y, jagnit R, chaudhari A. Formulation Evaluation & Optimization Of Vildagliptin Sustained-release Tablet. International Journal of Pharmaceutical Sciences. 2024. 2, 3086-3103. doi: 10.5281/zenodo.13313360.
Circioban, D., Ledeți, A., Ridichie, A. et al. Compatibility study of mirtazapine with several excipients used in pharmaceutical dosage forms employing thermal and non-thermal methods. J Therm Anal Calorim (2024). doi: 10.1007/s10973-024-13181-w.
Ameeduzzafar, El-Bagory I, Alruwaili NK, Elkomy MH, Ahmad J, Afzal M, et al. Development of novel Dapagliflozin loaded solid self-nanoemulsifying oral delivery system: Physiochemical characterization and in vivo antidiabetic activity. J Drug Deliv Sci Technol. 2019 Dec 1;54. Available at: https://api.semanticscholar.org/CorpusID:203129427.
Altoum GH, AL-Enazi FK, Abudahash MM, AL-Fadhli RA, Alenzi N. A comparative study on Vildagliptin brand and its generic equivalents using dissolution test as quality control measure tool. Sci Rep. 2024 Dec 1;14(1). doi: 10.1038/s41598-024-52674-4.
Tanajak P, Sa-nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattipakorn SC, et al. Cardioprotection of Dapagliflozin and Vildagliptin in rats with cardiac ischemia-reperfusion injury. Journal of Endocrinology. 2018 Feb 1;236(2):69–84. doi: 10.1530/JOE-17-0457.
SreeHarsha N, Hiremath JG, Sarudkar S, Attimarad M, Al-Dhubiab B, Balachandran Nair A, et al. Spray Dried Amorphous Form of Simvastatin: Preparation and Evaluation of the Buccal Tablet. Indian Journal of Pharmaceutical Education and Research. 2019 Dec 31;54(1):46–54.
Vildagliptin: Uses, Interactions, Mechanism of Action | DrugBank. Available from: https://go.drugbank.com/drugs/DB04876
Dapagliflozin: Uses, Interactions, Mechanism of Action | DrugBank. Available from: https://go.drugbank.com/drugs/DB06292
Publication & Comment Schedule | USP-NF. Available from: https://dev.uspnf.com/publication-comment-schedule
Shrestha P, Islam A, Selim Reza M, Adhikari S. Design and Development of Immediate and Sustained Release Tablets of Vildagliptin ARTICLE in RESEARCH JOURNAL OF PHARMACEUTICAL, BIOLOGICAL AND CHEMICAL SCIENCES. doi: 10.25258/ijpqa.12.4.14